{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:12:03Z","timestamp":1790871123074,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0310101"],"award-info":[{"award-number":["JP20fk0310101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["AMED JP19fk0310101"],"award-info":[{"award-number":["AMED JP19fk0310101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["19H03640"],"award-info":[{"award-number":["19H03640"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jhep.2021.02.017","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T11:17:49Z","timestamp":1616325469000},"page":"302-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation"],"prefix":"10.1016","volume":"75","author":[{"given":"Takako","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Iio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.02.017_bib1","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.jhep.2021.02.017_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-147-1-200707030-00010","article-title":"The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points","volume":"147","author":"Lai","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2021.02.017_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.017_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/genes10050357","article-title":"The role of hepatitis B core-related antigen","volume":"10","author":"Inoue","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.jhep.2021.02.017_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.02.017_bib6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2893.2003.00437.x","article-title":"Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment","volume":"10","author":"Rokuhara","year":"2003","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.02.017_bib7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.02.017_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.017_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5009\/gnl18425","article-title":"New biomarkers of chronic hepatitis B","volume":"13","author":"Mak","year":"2019","journal-title":"Gut Liver"},{"key":"10.1016\/j.jhep.2021.02.017_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis","volume":"58","author":"Kumada","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.017_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/apt.15108","article-title":"Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues","volume":"49","author":"Hosaka","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.02.017_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.13277","article-title":"Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma","volume":"49","author":"Suzuki","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.02.017_bib13","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/JCM.00726-13","article-title":"Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance","volume":"51","author":"Shinkai","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2021.02.017_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jhep.2020.03.009","article-title":"Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma","volume":"73","author":"Kusumoto","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.017_bib15","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/liv.13349","article-title":"Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay","volume":"37","author":"Shinkai","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.02.017_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load","volume":"40","author":"Kimura","year":"2002","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2021.02.017_bib17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1128\/JCM.41.5.1901-1906.2003","article-title":"New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA","volume":"41","author":"Kimura","year":"2003","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2021.02.017_bib18","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.M501564200","article-title":"Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain","volume":"280","author":"Kimura","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2021.02.017_bib19","first-page":"19","article-title":"High functional stability of a low-cost HBV DNA qPCR primer pair and plasmid standard","volume":"6","author":"Aguiar","year":"2016","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.jhep.2021.02.017_bib20","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","author":"Wong","year":"2007","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2021.02.017_bib21","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1440-1746.2005.04087.x","article-title":"Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection","volume":"20","author":"Rokuhara","year":"2005","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.02.017_bib22","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.02.017_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/liv.13046","article-title":"Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"36","author":"Chuaypen","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.02.017_bib24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2021.02.017_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12072-012-9354-7","article-title":"Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay","volume":"7","author":"Seto","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2021.02.017_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2018.07.011","article-title":"Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in\u00a0vitro","volume":"158","author":"Corcuera","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2021.02.017_bib27","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/ajg.2016.436","article-title":"Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy","volume":"111","author":"Seto","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.02.017_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13574","article-title":"Hepatitis B core-related antigen to detect hepatitis B virus (HBV) reactivation in heart transplant recipients with past HBV infection: a pilot study","volume":"33","author":"Iossa","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhep.2021.02.017_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00272-18","article-title":"Common and distinct capsid and surface protein requirements for secretion of complete and genome-free hepatitis B virions","volume":"92","author":"Ning","year":"2018","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.02.017_bib30","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1073\/pnas.84.9.2678","article-title":"Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA","volume":"84","author":"Yaginuma","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2021.02.017_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2020.04.045","article-title":"Assay for hepatitis B core-related antigen identify patients with high viral load: systematic review and meta-analysis of individual participant data","volume":"19","author":"Yoshida","year":"2021","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821001513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821001513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:55:35Z","timestamp":1777510535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0168827821001513"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.02.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}